ClinicalTrials.gg
TerminatedNCT04905212Updated Dec 6, 2023

A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy

A Phase 2 interventional study of Telitacicept 160mg and Telitacicept 240mg in IgA Nephropathy, sponsored by RemeGen Co., Ltd.. Terminated at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-06.

Sponsored by RemeGen Co., Ltd. · Phase 2, Interventional, and Treatment

Why this study was terminated
Decision that continuing with the study would not generate useful data

From the registry’s dates

  • Primary completion was Nov 2023, 3 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 74 studies in Glomerulonephritis, IGA with a site in United States — 26 open to participants now, 38 under way, 17 of them phase 3. Glomerulonephritis, IGA · United States.

Enrollment
61st of 68
15 · median 64
Started
2021
with 6 others
Phase 2
30 of 74
11 open now
Registered
33rd of 74
by date

Among the 74 studies in Glomerulonephritis, IGA with a site in United States, this one is the 61st largest by enrollment of the 68 interventional ones that give a count, is one of 7 that started in 2021, is one of 30 in phase 2, and was the 33rd registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

26 of the 74 studies in Glomerulonephritis, IGA with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies in Glomerulonephritis, IGA with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical study with an optional open label extension to evaluate the safety and efficacy of Telitacicept for Injection (RC18) in the treatment of IgA nephropathy.

Read the detailed description

IgA nephropathy is a kidney disease in which IgA, a protein meant to defend the body against foreign invaders, accumulates in the kidneys and damages them. This study will seek to determine the safety and efficacy of Telitacicept for Injection (RC18) in the treatment of IgA nephropathy.

The study is composed of 4 parts: a screening period, a double-blind treatment period, an optional open label extension, and a follow-up period. Subjects with confirmed IgA nephropathy will be enrolled and randomized 1:1:1 to Telitacicept 160 mg, Telitacicept 240 mg, or placebo (10 per arm).

03

Conditions studied

  • IgA Nephropathy

Keywords

  • Berger Disease
  • Berger's Disease
  • IGA Glomerulonephritis
  • IGA Nephropathy
  • Primary IGA Nephropathy
  • Immunoglobulin A Nephropathy Nephritis
  • IGA Type Nephropathy, IGA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. IgA nephropathy confirmed by pathological ;
  2. Male or female aged ≥ 18 years old;
  3. Average 24-hour urine total protein ≥ 0.75 g/24 h
  4. Estimated (using the CKD-EPI formula) > 30 mL/min per 1.73 m\^2;
  5. Stabilized AEI/ARB medications, diuretics, or other antihypertensive therapy.

Exclusion criteria

Exclusion Criteria:

  1. Patients with abnormal laboratory tests at screening;
  2. Evidence of rapid decrease > 15 ml/min during screening;
  3. Renal or other organ transplantation prior to, or expected during, the study;
  4. Patients with secondary IgA nephropathy;
  5. Patients with nephrotic syndrome, crescentic nephritis minimal change nephropathy with IgA deposition, or other pathological or clinical types of renal diseases that may confound the study data interpretation;
  6. Patients with history of any severe unstable cardiovascular and cerebrovascular events within 12 weeks prior to screening;
  7. individuals.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Telitacicept 160mg

    Telitacicept 160mg subcutaneous injection once weekly, and a total of 24 doses

    Drug: Telitacicept 160mg

  • Experimental
    Telitacicept 240mg

    Telitacicept 240mg subcutaneous injection once weekly, and a total of 24 doses

    Drug: Telitacicept 240mg

  • Placebo comparator
    Placebo

    Placebo subcutaneous injection once weekly, and a total of 24 doses

    Drug: Placebo

Interventions

  • Subcutaneous injection Telitacicept 160mg. The injection site can be at the thigh, abdomen, or upper arm.

  • Subcutaneous injection Telitacicept 240mg. The injection site can be at the thigh, abdomen, or upper arm.

  • DrugPlacebo

    Subcutaneous injection placebo. The injection site can be at the thigh, abdomen, or upper arm.

06

What researchers measure

Primary outcomes

  1. Change from baseline in 24-hour urine protein at Week 24.

    Change from baseline in urine protein over 24 hours to Week 24 will be measured

    Time frame: Week 24

Secondary outcomes

  1. Change from baseline in estimated glomerular filtration rate (eGFR) at Weeks 4, 8, 12, 16, 20, 24, 32, 36 and 48

    Change from baseline in eGFR by visit

    Time frame: Weeks 4, 8, 12, 16, 20, 24, 32, 36 and 48

  2. Change from baseline in urine protein-to-creatinine ratio (UPCR) and urine albumin-to-creatinine ratio (UACR) at Weeks 4, 8, 12, 16, 20, 24, 32, 36, and 48;

    Change from baseline in Urine protein-to-creatinine ratio (UPCR) and Urine albumin-to-creatinine ratio (UACR) by visit.

    Time frame: Weeks 4, 8, 12, 16, 20, 24, 32, 36, and 48

  3. Change from baseline in immunological parameters (IgA, IgG, IgM, C3, C4, and B lymphocytes) at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 48, and EOT visit.

    Changes from baseline in Immunoglobulins (IgA, IgG, IgM), B lymphocytes (CD19+), complements (C3, C4)

    Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 48, and EOT visit.

Other outcomes

  1. The incidence and severity of adverse events

    Number and intensity of adverse events

    Time frame: 27 weeks

  2. Immunogenicity endpoints

    Anti-drug antibody (ADA), incidence, titers and duration

    Time frame: Week 0, 4, 8, 12, 16, 20, 24 and 27

  3. Biomaker endpoints serum concentration

    BLyS serum concentration, APRIL serum concentration, and BLyS-drug complex

    Time frame: Week 0, 4, 8, 12, 16, 20, and 24

  4. Pharmacokinetic endpoints

    Free Telitacicept serum concentration and total Telitacicept serum concentration

    Time frame: Week 0, 4, 8, 12, 16, 20, 24 and 27

07

Study locations

8 sites
  • Remegen Site #5
    Los Angeles, California 90022, United States
  • Remegen Site #13
    Los Angeles, California 91324, United States
  • Remegen Site #14
    Los Angeles, California 91324, United States
  • Remegen Site #10
    Sacramento, California 95687, United States
  • Remegen Site #8
    San Francisco, California 94080, United States
  • Remegen Site #16
    Fort Lauderdale, Florida 33071, United States
  • Remegen Site #17
    Augusta, Georgia 30909, United States
  • Remegen Site #2
    Philadelphia, Pennsylvania 17033, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Nov 2023, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2021
First posted
May 27, 2021
StartActual
Nov 4, 2021
Primary completionActual
Nov 9, 2023
CompletionActual
Nov 9, 2023
Last update
Dec 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04905212
Lead sponsor
RemeGen Co., Ltd.
Responsible party
Sponsor
First posted
May 27, 2021
Start date
Nov 4, 2021
Primary completion
Nov 9, 2023
Completion
Nov 9, 2023
Last update
Dec 6, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telitacicept

Start the discussion